RecruitingNot ApplicableNCT05613010

Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant

Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients: A Micro-Randomized Trial

Sponsor

Johns Hopkins University

Enrollment

65 participants

Start Date

Mar 19, 2024

Study Type

INTERVENTIONAL

Conditions

Adherence, Treatment Adherence, Medication Transplant;Failure,Kidney Adherence, Patient Transplant; Failure, Liver

Summary

Can the investigators create an effective way to improve adherence to immunosuppressant medication and reduce rejection, graft loss, and death in adolescents and young adults who have undergone kidney or liver transplantation? The investigators' mobile technology intervention uses real-time electronic pillbox-assessed dose timing and text message prompts to address antirejection medication nonadherence when nonadherence is detected.

Eligibility

Min Age: 13 YearsMax Age: 25 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a behavioral approach called mHealth Messaging Intervention Group for people with adherence, medication, adherence, patient, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 13 Years to 25 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALmHealth Messaging Intervention Group

Participants will receive an electronic pill box; the research team will instruct participants on how to use this device. Participants will be asked to use the electronic pill box for their prescribed medicines for the duration of the study (up to 16 months). During the 12-week micro-randomized trial, participants will be randomized within person to receive (1) adherence support text messages or (2) no text message after each missed dose, and (1) praise text message or (2) no text message after each on time dose. Dose timing will be determined based on participant report of when they typically take their tacrolimus or sirolimus medicine.